1. Home
  2. XLO vs GIFT Comparison

XLO vs GIFT Comparison

Compare XLO & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • GIFT
  • Stock Information
  • Founded
  • XLO 2016
  • GIFT 1999
  • Country
  • XLO United States
  • GIFT United States
  • Employees
  • XLO N/A
  • GIFT N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • GIFT Catalog/Specialty Distribution
  • Sector
  • XLO Health Care
  • GIFT Consumer Discretionary
  • Exchange
  • XLO Nasdaq
  • GIFT Nasdaq
  • Market Cap
  • XLO 40.9M
  • GIFT 33.9M
  • IPO Year
  • XLO 2021
  • GIFT N/A
  • Fundamental
  • Price
  • XLO $0.80
  • GIFT $1.15
  • Analyst Decision
  • XLO Buy
  • GIFT Strong Buy
  • Analyst Count
  • XLO 2
  • GIFT 1
  • Target Price
  • XLO $3.00
  • GIFT $4.00
  • AVG Volume (30 Days)
  • XLO 604.4K
  • GIFT 115.0K
  • Earning Date
  • XLO 11-07-2025
  • GIFT 11-13-2025
  • Dividend Yield
  • XLO N/A
  • GIFT N/A
  • EPS Growth
  • XLO N/A
  • GIFT N/A
  • EPS
  • XLO N/A
  • GIFT N/A
  • Revenue
  • XLO $15,001,000.00
  • GIFT $90,569,384.00
  • Revenue This Year
  • XLO $519.70
  • GIFT $5.90
  • Revenue Next Year
  • XLO $44.57
  • GIFT $13.45
  • P/E Ratio
  • XLO N/A
  • GIFT N/A
  • Revenue Growth
  • XLO 536.45
  • GIFT 8.55
  • 52 Week Low
  • XLO $0.62
  • GIFT $0.82
  • 52 Week High
  • XLO $1.70
  • GIFT $2.38
  • Technical
  • Relative Strength Index (RSI)
  • XLO 52.39
  • GIFT 55.60
  • Support Level
  • XLO $0.73
  • GIFT $1.10
  • Resistance Level
  • XLO $0.90
  • GIFT $1.22
  • Average True Range (ATR)
  • XLO 0.06
  • GIFT 0.08
  • MACD
  • XLO 0.00
  • GIFT 0.01
  • Stochastic Oscillator
  • XLO 41.23
  • GIFT 63.16

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About GIFT RDE Inc. Common Stock

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

Share on Social Networks: